Back Back
2022 WCLC Highlights

CME

Independent Conference Coverage of the IASLC 2022 World Conference on Lung Cancer

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: October 25, 2022

Expiration: October 24, 2023

Wade T. Iams
Wade T. Iams, MD, MSCI
Heather Wakelee
Heather Wakelee, MD
CME/CE Information

Activity

Progress
1
Course Completed

In this module, Wade T. Iams, MD, MSCI, and Heather Wakelee, MD, FASCO, discuss key findings in lung cancer presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC), including updates in non-small-cell lung cancer (NSCLC), both for early-stage and advanced disease, as well as small-cell lung cancer (SCLC).

Please note that the key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with lung cancer do you see in a typical month?

In the phase III IMpower010 trial, the largest trend towards an overall survival (OS) benefit with adjuvant atezolizumab vs best supportive care (BSC) in patients with completely resected stage II-IIIA NSCLC was seen in which of the following subpopulations by PD-L1 expression at the first OS interim analysis?

A 60-year-old woman with a smoking history was diagnosed with advanced NSCLC with 70% PD-L1 and next-generation sequencing (NGS) results positive for a KRAS G12V mutation. She began therapy with single-agent pembrolizumab, achieved a partial response (PR), and has completed 30 cycles. What can you tell her about the potential to resume pembrolizumab at disease progression once she completes 35 cycles of pembrolizumab?

Which of the following findings was reported from the phase Ib CodeBreaK101 trial assessing the combination of sotorasib and the SHP2 inhibitor RMC-4630 in patients with locally advanced or metastatic KRAS G12C mutation–positive NSCLC after previous systemic therapy, including previous anti–PD-1/PD-L1 and/or platinum-based chemotherapy and targeted therapy?
BACK | NEXT